Business Context and Reporting Period
Company: Genmab A/S (GMAB)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Accounting Standards: IFRS (International Financial Reporting Standards)
Reporting Currency: US Dollars (changed from Danish Kroner as of January 1, 2025)
Genmab is an international biotechnology company focused on antibody-based products for cancer and serious diseases. The company operates a hybrid business model, generating revenue through royalties from partnered products (primarily DARZALEX) and net product sales from proprietary commercial products (EPKINLY and Tivdak). A defining event of the period was the acquisition of Merus N.V. on December 12, 2025, for approximately $8.0 billion, adding the product candidate petosemtamab and the approved product BIZENGRI to the portfolio.
Key Financial Metrics
Note: Specific revenue, profit, and cash flow figures for the fiscal year 2025 are incorporated by reference to the Annual Report 2025 (pages 38-46) and are not explicitly stated in the provided text. The following metrics are derived from the text where available.
- Revenue Composition: The majority of revenue is derived from royalties on DARZALEX sales (66% of revenue in 2025). Additional revenue streams include net product sales (EPKINLY, Tivdak), milestone payments, and collaboration revenue.
- Debt and Liquidity: To finance the Merus acquisition, Genmab incurred substantial indebtedness in December 2025:
- $1.0 billion Term Loan A Facility
- $2.0 billion Term Loan B Facility
- $0.5 billion Revolving Credit Facility
- $1.5 billion Senior Secured Notes
- $1.0 billion Senior Unsecured Notes
- Capital Structure: As of the close of the period, there were 64,238,408 Ordinary Shares and 64,377,450 American Depositary Shares (ADS) outstanding.
- Employee Count: 3,029 employees as of December 31, 2025 (up from 548 in 2019).
Material Changes vs. Prior Period
- Acquisition of Merus: Completed on December 12, 2025. This transaction significantly increased the company's asset base (Merus assets constituted 59.6% of total assets at year-end) and added substantial debt. It also expanded the pipeline with petosemtamab (HNSCC) and BIZENGRI (NRG1+ cancer).
- Commercialization Expansion: Genmab assumed sole responsibility for the development and commercialization of Tivdak in Europe and most global regions (excluding US and China) effective January 1, 2025. Tivdak was launched in Japan and Germany in 2025.
- Product Approvals:
- EPKINLY (epcoritamab): Received full FDA approval for Follicular Lymphoma (FL) in November 2025. Approved in combination with R2 for second-line FL in November 2025.
- Tivdak (tisotumab vedotin): Received full FDA approval in April 2024 (converted from accelerated) and regulatory approval in Japan and Europe in 2024/2025.
- Portfolio Rationalization: Discontinued further clinical development of acasunlimab in December 2025 to focus on late-stage value-creating opportunities.
- Share Repurchases: Completed a share buy-back program in 2025, repurchasing 2,200,000 ordinary shares to reduce capital and honor RSU commitments.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary
Management expects the acquisition of Merus to increase R&D and SG&A expenses in the short-to-medium term due to the development of petosemtamab. Despite these costs, the company expects to maintain positive operating earnings and cash flow generation driven by its royalty business and proprietary products. The company anticipates that royalties from DARZALEX will begin to decline materially in 2029 following the expiration of US patent rights.
Key Risks
- Patent Expiration: DARZALEX royalties are the primary revenue driver (66% in 2025). US patents expire in 2029, European in 2031, and Japanese in 2030. Biosimilar competition is expected to reduce royalties upon patent expiry or earlier if biosimilars launch.
- Indebtedness: The substantial debt incurred for the Merus acquisition limits financial flexibility, increases interest expense, and imposes restrictive covenants (e.g., limitations on dividends and additional indebtedness).
- Regulatory and Pricing: Risks include the US Inflation Reduction Act (IRA) allowing Medicare price negotiation (effective 2026) and the US administration's push for Most-Favored-Nation (MFN) pricing, which could lower drug prices.
- Legal Proceedings:
- AbbVie Litigation: AbbVie filed complaints in the US District Court and with the US International Trade Commission (ITC) alleging misappropriation of trade secrets related to Rina-S and ADC technology. Genmab denies these allegations.
- Chugai Litigation: Chugai filed lawsuits in Japan alleging patent infringement regarding EPKINLY. Genmab intends to defend vigorously.
- Integration Risk: Failure to realize anticipated benefits from the Merus acquisition or successfully integrate petosemtamab development could adversely affect financial results.
Investor Verification Checklist
- Debt Covenants: Verify the specific financial maintenance covenants in the new credit facilities and notes to ensure compliance and understand restrictions on future capital allocation.
- Merus Integration: Monitor the progress of petosemtamab Phase III trials (LiGeR-HN1 and LiGeR-HN2) and the integration of Merus operations, as these are critical to justifying the $8 billion acquisition.
- DARZALEX Royalty Trajectory: Track J&J's sales of DARZALEX and monitor for any early biosimilar launches or patent challenges that could accelerate the expected revenue decline post-2029.
- Legal Outcomes: Follow the status of the AbbVie trade secret litigation and the Chugai patent disputes, as adverse outcomes could impact the Rina-S and EPKINLY programs.
- EPKINLY Commercialization: Assess the commercial uptake of EPKINLY in the US and Japan, particularly following its full approval for FL and the new second-line combination indication.
- Regulatory Pricing Impact: Evaluate the potential impact of the US IRA and MFN pricing initiatives on the net sales of DARZALEX and other partnered products.